Caremark Reaps Pricing Benefit From AdvancePCS Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The PBM is looking for additional mergers and acquisitions outside pharmacy benefit management.
You may also be interested in...
Statin Prices Likely To Remain High After Zocor Exclusivity Win
Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.
Teva Launches Generic Pravachol Following Appeals Court Dismissal Of Apotex
Watson concurrently launched an authorized generic of Bristol's pravastatin, but Ranbaxy's 80 mg ANDA remains on hold.
Caremark To Implement New Business Practices Under Settlement With U.S. Attorney
The $137.5 mil. settlement requires Caremark to inform client plans of rebates earned as a percentage of the PBM’s total product revenue.